Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2, Open-Label, Dose-Finding Followed by 2-Year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Adolescent Subjects With Stargardt Disease

NCT05266014 is registered in ClinicalTrials.gov with RBP4 Pty Ltd as lead sponsor.

NCT NCT05266014
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05266014 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2, Open-Label, Dose-Finding Followed by 2-Year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Adolescent Subjects With Stargardt Disease
Lead sponsor
RBP4 Pty Ltd
Phase
Phase 1/2
Overall status
Completed
Start date
March 12, 2021
Completion date
August 15, 2023
Enrollment
13 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

stargardt disease